Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Fred Hutch Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Mustang Bio: Positive Data from Waldenstrom Macroglobulinemia CAR-T Trial
Details : MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of Waldenstrom macroglobulinemia.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 17, 2024
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Fred Hutch Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mustang Bio Announces Vision for Expanding CAR T-Cell Platform into Autoimmune Diseases
Details : MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of autoimmune diseases.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 28, 2024
Lead Product(s) : MB-106
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 16, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : uBriGene
Deal Size : $11.0 million
Deal Type : Agreement
Details : Under the agreement, uBriGene gains access to all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies, including MB-106, a first-in-class CD20-targeted autologous CAR T therapy.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : $6.0 million
July 31, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : uBriGene
Deal Size : $11.0 million
Deal Type : Agreement
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Fred Hutchinson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 15, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Fred Hutchinson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Fred Hutchinson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with Waldenstrom macroglobulinemia.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 12, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Fred Hutchinson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-106, first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“BNHL”) and chronic lymphocytic leukemia.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 06, 2022
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The overall response for MB-106 was 96% across all dose levels and all indications. In particular, 100% complete response rates by PET scan of patients with WM (n=2) as well as of patients with B-NHL previously treated with CD19- directed CAR T cell ther...
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 22, 2022
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The lentiviral vector drug substance used to transduce patients’ cells to create the MB-106, produced at Fred Hutch has been optimized as a third-generation CAR derived from a fully human antibody, and MB-106 is currently in a Phase 1/2 in patients wit...
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 13, 2022
Lead Product(s) : MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-106 showed Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 12, 2022
Lead Product(s) : MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?